Cabaletta Bio, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted net-asset approach: pro forma cash of ~$266.6M (Q1 2026 cash plus the May 2026 $150M raise) divided by 169.5M shares = $1.57/share cash floor, plus a ~50% pipeline option premium for the RESET-Myositis program nearing a registrational BLA (targeted 2027) with Fast Track and RMAT designations.

Reasoning: Cabaletta Bio is a pre-revenue, cash-burning clinical-stage cell-therapy company, so a standard FCF DCF cannot be built; value is anchored to its cash position with a moderate premium reflecting the de-risked, late-stage status of its lead autoimmune-disease program relative to its earlier-stage pipeline assets.